Cargando…
Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan
Hepatic resection or liver transplantation for hepatocellular carcinoma (HCC) represents the only chance for achieving a cure. For the past several decades in Japan, aggressive hepatic resection has been performed for advanced HCC, with consequent good outcomes. According to the 21st Nationwide Foll...
Autor principal: | Taketomi, Akinobu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355680/ https://www.ncbi.nlm.nih.gov/pubmed/34414318 http://dx.doi.org/10.31662/jmaj.2021-0035 |
Ejemplares similares
-
Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
por: Liu, Ze-Long, et al.
Publicado: (2021) -
The Extended Surgical Concepts for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
por: Hsu, Hsiao-Mei, et al.
Publicado: (2023) -
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022) -
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
por: Repáraz, David, et al.
Publicado: (2022) -
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
por: van Doorn, Diederick J., et al.
Publicado: (2020)